Mass General Brigham

Simplifying healthcare administration with intuitive tech tools

Hospital Management

Carta healthcare is a San Francisco-based provider of clinical data management solutions founded in 2017. The company offers three main products - Atlas, Navigator, and Semaphore, powered by its Cartographer analytics platform. Atlas is an AI-powered data abstraction tool that helps hospitals submit patient data to clinical registries efficiently and accurately. Navigator analyzes healthcare organizations' data to provide recommendations for improving operational workflows. Semaphore, introduced in September 2022, is a development platform that enables healthcare organizations to create custom data science tools and AI models.
Carta's technology uses AI to streamline data entry tasks, reducing the administrative burden on nurses and clinicians. The AI replicates the work of data abstractors, allowing healthcare professionals to spend more time on patient care. However, Carta's approach involves a combination of AI and human verification, as clinician input is required for certain data fields to maintain accuracy.
Carta's solutions have been deployed across 245 hospitals within 18 health systems as of November 2022, including Stanford healthcare, Mass General Brigham, CommonSpirit Health, and UCSF Health. The company has demonstrated cost savings for its customers, with Stanford healthcare reportedly saving USD 4 million by optimizing surgical supply management using Carta's technology.

CodaMetrix provides an artificial intelligence (AI) powered platform for autonomous medical coding across multiple specialties, including radiology, pathology, surgery, gastroenterology, and inpatient professional coding. The company's technology utilizes machine learning, deep learning, and natural language processing to analyze clinical notes and patient records, automatically assigning appropriate medical codes for billing and insurance purposes.
CodaMetrix's platform aims to address the inefficiencies and challenges faced by healthcare providers in the revenue cycle management process. Medical coding is a time-consuming and error-prone task, often leading to claim denials, delayed payments, and administrative burden on healthcare professionals. By automating the coding process, CodaMetrix enables providers to reduce coding costs by up to 60%, decrease claim denials by 70%, and accelerate time to cash by five weeks on average.
Founded in 2019 and initially developed at Massachusetts General Brigham (MGB), CodaMetrix has since partnered with leading healthcare systems across the US. As of March 2024, the company's platform is utilized by over a dozen provider organizations and health systems, representing more than 200 hospitals and 50,000 providers. Notable clients include MGB, University of Colorado Medicine, Mount Sinai Health System, Yale Medicine, Henry Ford Health, and the University of Miami Health System.
In March 2024, CodaMetrix secured USD 40 million in Series B funding led by Transformation Capital, bringing the company's total funding to USD 95 million. The capital raised will be utilized to further enhance CodaMetrix's AI solutions, improve coding quality, enrich claims data with clinical insights, and alleviate administrative burdens on healthcare providers.

Abridge is a pioneering healthcare technology company that has developed an AI-powered platform to transform medical conversations into structured clinical notes in real-time. The company's proprietary technology leverages machine learning and natural language processing to accurately transcribe and summarize patient-clinician interactions, extracting key medical information and mapping it to relevant codes and ontologies.
Abridge's core offering is an enterprise-grade documentation solution that seamlessly integrates with electronic health record (EHR) systems like Epic. During a medical encounter, the platform records the conversation and generates a draft clinical note, capturing details such as the patient's medical history, diagnoses, treatments, and follow-up instructions. This automated process significantly reduces the administrative burden on healthcare providers, saving them an average of two hours per day on documentation tasks.
The company's technology has been extensively trained on a proprietary dataset derived from over 1.5 million medical encounters, enabling it to perform accurately across a wide range of specialties and support multiple languages. Abridge's platform includes a "Linked Evidence" feature that maps AI-generated summaries to the corresponding sections in the source transcript, allowing providers to quickly verify the accuracy of the information.
Since its founding in 2018, Abridge has rapidly gained traction among healthcare providers and systems. As of March 2024, the company's solutions were being used by around 5,000 doctors across various health systems.
In February 2024, Abridge announced a strategic partnership with Epic, enabling seamless integration of its generative AI for clinical documentation into Epic's EHR workflow. This collaboration has facilitated rapid deployments across multiple healthcare systems, with full implementation often achieved within two weeks.
Key customers and partnerships
Abridge has established notable partnerships with several leading healthcare organizations and technology companies, including:
- Sutter Health
- Yale New Haven Health System
- UCI Health
- Emory healthcare
- The University of Kansas Health System and UPMC
- Epic
- Nvidia

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

<div>
 
 Health Catalyst is a provider of data and analytics technology and services for healthcare organizations. The company offers a population health management platform that uses analytic insights to predict patient needs and manage patient flow. It identifies populations at risk and takes necessary interventions to prevent and manage chronic diseases.&nbsp;
 
 
 The Population Health Suite includes tools such as Value Optimizer for analyzing cost of care, MeasureAble for regulatory measure, and Pop Analyzer: Stratify for predictive assessment. Furthermore, the cloud-based data platform leverages data from over 100 million patient records encompassing trillions of facts.&nbsp;
 
 
 In 
 <a href="https://sp-edge.com/updates/30288">
 June 2024
 </a>
 , the company acquired Carevive Systems, an oncology-focused health technology company, to expand its cancer care offerings.&nbsp;
 
 
 Key customers and partnerships
 
 
 As of May 2024, Health Catalyst had served over 250 hospitals and 3,000 clinics in the US.
 
 
 Key customers and partnerships
 
 
 <a href="https://sp-edge.com/updates/16801">
 In February 2023
 </a>
 , the company announced a multi-year contract expansion with non-profit healthcare organization Integris Health&nbsp; to enhance the analytics abilities of Integris&rsquo;s health network by increasing access to technology and hiring specialized staff. Furthermore, in July 2022, Ohio-based Akron Children&rsquo;s Hospital partnered with Health Catalyst to implement Health Catalyst&rsquo;s suite of population health solutions.
 
</div>

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

Abridge is a Pittsburgh-based startup that develops GenAI tools for medical documentation. The company's core product is an AI-powered platform that converts patient-clinician conversations into structured clinical notes in real time. The technology integrates seamlessly with electronic health record systems, allowing clinicians to review and verify the AI-generated notes before finalizing them. Abridge's solution aims to reduce the administrative burden on healthcare providers, potentially saving them <a href="https://www.abridge.com/">70 hours per month</a> on documentation tasks. The platform supports <a href="https://www.abridge.com/">over 14 languages</a> and more than <a href="https://www.abridge.com/">50 medical specialties</a>.&nbsp;The company's technology is built on a proprietary data set derived from over 1.5 million medical encounters, and it employs advanced natural language processing and machine learning techniques to ensure accuracy and efficiency in clinical documentation.Key customers and partnershipsAs of <a href="https://www.fiercehealthcare.com/ai-and-machine-learning/abridge-clinches-150m-build-out-generative-ai-medical-documentation#:~:text=Around%205%2C000%20doctors%20currently%20use,Rao%2C%20a%20cardiologist%2C%20noted.">February 2024</a>, the company’s solution was being used by around 5,000 clinicians.In <a href="https://sp-edge.com/updates/35580">October 2024</a>, Abridge partnered with OpenNotes, a health transparency research organization at BIDMC, to improve patient visit documentation. The partnership, part of BIDMC's new OpenNotes Lab initiative, would evaluate Abridge's AI-generated patient visit summaries through focus groups to enhance their usefulness and accessibility.&nbsp;Also in <a href="https://sp-edge.com/updates/34809">October 2024</a>, the company partnered with Wolters Kluwer Health to integrate UpToDate, a clinical decision support solution, into its platform. Through the partnership, Abridge's AI-generated clinical notes would include links to relevant evidence-based recommendations from UpToDate, providing clinicians with immediate access to the latest clinical information at the point of care.&nbsp;In <a href="https://www.reidhealth.org/press-releases/reid-health-chooses-abridge-generative-ai-solution-to-increase-access-to-care">August 2024</a>, Abridge partnered with Reid Health, a rural healthcare system, to implement AI-powered solutions across Reid's network. Through the partnership, Abridge's AI technology was integrated with Epic's workflow, automating clinical documentation in real-time. The partnership aimed to reduce clinicians' administrative burden, allowing Reid Health to focus more on patient care.In <a href="https://www.abridge.com/press-release/abridge-mayo-epic">July 2024</a>, the company partnered with health IT giant Epic and healthcare system Mayo Clinic to create a GenAI documentation platform. The partnership aimed to integrate Abridge's AI transcription and documentation tools into Epic's EHR workflow for Mayo Clinic's nurses. The GenAI tool utilized Abridge's technology to automatically transcribe and summarize conversations between nurses and patients while leveraging Epic's expertise in EHR integration and Mayo Clinic's knowledge of nursing practices.In <a href="https://www.abridge.com/press-release/uvm-health-network-announcement">June 2024</a>, Abridge partnered with The University of Vermont Health Network to improve clinician well-being. Through the partnership, Abridge's AI-powered platform was deployed across the university’s health network to generate clinical notes from patient-clinician conversations in real-time. The company noted that the enterprise-wide rollout would initially cover primary care and later expand to specialties like cardiology and endocrinology.In <a href="https://www.abridge.com/press-release/abridge-sutter-health">March 2024</a>, Abridge partnered with not-for-profit health system Sutter Health, to implement Abridge’s AI platform for clinical documentation across Sutter's network in California.

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. The company's proprietary LYNX drug delivery platform enables the creation of medicines that can last for a week or longer in an oral dosage form. This platform represents a significant advance in oral drug delivery, aiming to dramatically reduce dosing frequency compared to traditional daily pills. Lyndra's lead product candidate is oral weekly risperidone (LYN-005), which is being developed for the treatment of schizophrenia and bipolar I disorder. In January 2024, Lyndra reported positive results from the Phase III STARLYNG-1 clinical trial of LYN-005, meeting its primary endpoint. The company is also developing other long-acting oral therapies, including oral weekly dapagliflozin (LYN-045) for diabetes and oral weekly aripiprazole (LYN-006) for mental health conditions. Additionally, Lyndra is working on oral biweekly ivermectin (LYN-163) as a potential tool in the fight against malaria. The LYNX platform originated from technology invented at the Massachusetts Institute of Technology (MIT) and has progressed rapidly since 2015 through preclinical and human studies. Lyndra has a state-of-the-art GMP manufacturing facility in Lexington, Massachusetts.
Key customers and partnerships
Lyndra Therapeutics has established partnerships with several notable organizations to advance its long-acting oral therapies. The company has received product funding from the Bill & Melinda Gates Foundation, particularly for the development of oral biweekly ivermectin. In December 2023, as part of a USD 101 million Series E financing round, Lyndra entered into an agreement with Sun Pharmaceutical Industries Limited. This partnership grants Sun Pharma an exclusive license to manufacture and market Lyndra's oral weekly risperidone, dapagliflozin, and aripiprazole in six countries, including India and Brazil, pending further clinical development. Lyndra has previously received funding from AbbVie and Gilead Sciences, Inc., indicating potential interest from major pharmaceutical companies in its technology platform. The company's focus on developing therapies for conditions like schizophrenia, bipolar disorder, and opioid use disorder suggests potential future partnerships or customers in the mental health and addiction treatment sectors.

Enabling the health systems to seamlessly connect, exchange, and interpret shared data

Hospital Interoperability

<div>
 
 Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations. Its cloud-based data platform is powered by data from over 100 million patient records, encompassing trillions of facts. The platform combines best-in-class technologies, healthcare-specific data models, self-service tools, and industry expertise in a modern environment. In May 2024, Health Catalyst launched Ignite, a next-generation healthcare data and analytics ecosystem designed to address challenges faced by health systems.
 
 
 
 
 Ignite enables seamless integration and workflows, provides enhanced transparency and control over data management, and facilitates predictive insights through machine learning and AI. It streamlines data ingestion, centralizes data governance, democratizes analytics, reduces storage and management costs, and offers widespread access to refined healthcare data. Ignite is built for simplicity and utility, integrating clinical, financial, and operational data to support healthcare's most crucial use cases.
 
 
 
 
 Health Catalyst's technology empowers healthcare organizations to make data-informed decisions, driving measurable clinical, financial, and operational improvements. Its solutions shorten time to analytics, strengthen accuracy and trust, empower self-service analytics, and future-proof the analytics engine through continuous integration of new technologies and an adaptable data model.
 
 
 
 
 In February 2023, Health Catalyst announced a comprehensive, multi-year strategic partnership with Deaconess Health System. Through this five-year partnership, Deaconess will leverage Health Catalyst's enterprise analytics and outcomes improvement expertise to transform its clinical, operational, and financial domains.
 
</div>

Abridge is a medical conversation AI startup that offers an audio-based system to record and summarize medical conversations. It was created for everyone, with a mission to help better understand their health conversations, whether at home or in the hospital.

CodaMetrix is a creator of an AI-powered platform for healthcare revenue cycle management and medical coding. The company's platform combines machine learning, deep learning, and natural language processing to automatically, accurately, and autonomously translate clinical notes into billing and diagnostic codes that satisfy coding requirements while reducing human coding workload, allowing clinicians to improve efficiency and optimize medical coding quality.

Carta Healthcare empowers hospitals to personalize the delivery of care to the individual needs of each patient. The approach Carta Healthcare is advocating and enabling to find past patients similar to the current one being treated, quantify what exactly happened to them during their journey through the hospital (this is where our model comes in), and use machine learning to project what the particular patient in question will need, and what the patient can expect their experience to be in the hospital.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

Lyndra Therapeutics is a company that develops medicines for long-term drug release in an oral dose form. The company is developing oral ultra-long-acting and sustained-release therapies for central nervous system (CNS) disorders for broad applicability across multiple therapeutic areas, including approved drugs, allowing the medical community to ensure improved medication adherence and health outcomes while also helping to lower healthcare costs.

Health Catalyst is a tech platform that organizes and links health-related data from different systems. It helps organize, normalize, and link the data from all different systems and make it searchable by all users, even the non-technical.

T2 Biosystems is a private company developing a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single, easy-to-use instrument. The company's proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time-consuming sample preparation.

Provasculon was founded to exploit the discovery by Richard Lee, MD, a cardiologist at Brigham and Women's Hospital and Associate Professor at Harvard Medical School, and Vincent Segers, MD, a researcher at Brigham and Women's Hospital, of novel forms of the growth factor Stromal Cell-Derived Factor-1 (SDF-1).

Tattoos are all about self-expression and personal style; they're a way to showcase your unique point of view. And how many times have you changed your mind? Remember Angelina's ode to Billy Bob? We all know their love didn't last as long as the art commemorating it.  Freedom2 was founded nearly ten years ago with the crazy idea that a permanent tattoo might be removable. Typical tattoo ink is made from insoluble pigments and remains in the skin forever. Laser treatments can be costly and painful, and ultimately might not even remove the tattoo completely. Thinking that there's got to be a better alternative, our founders began pursuing the idea that there could be a way to make tattoos that were permanent, and less expensive to remove. And thus the idea of the Particle Encapsulation and Enhancement (P2E) Platform was born.

GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.

Radianse provides intelligent solutions for businesses with their real-time tracking services.  Their advanced software automatically collects and processes  a variety of live data on any asset.  The situation history is recorded and easily accessible through their Radianse Awareness Suite from any web-enabled device.  Their mission is to improve the way businesses operate by providing accessible, affordable, andcustomized solutions that automatically integrate data sources into real-time actionable intelligence.  They aim to be the market leader in the providing of situation awareness coupled with actionable intelligence.  Their goal is to deliver innovative, technology-based applications that allow their customers to manage their resources, control costs, increase revenue opportunities, and improve overall operational efficiency.  Radianse has achieved significant milestones in developing cutting-edge algorithms and methodologies to deliver reliable products with superior accuracy and performance.  All of their products are covered by one or more patents with additional U.S. and international patents pending.  Radianse is committed to constantly innovating and evolving.  They began as an engineering organization focused on Radio Frequency Identification (RFID) technology-based solutions.  Their aim was to automatically and continuously monitor high-value hospital assets.  Radianse now works with many clients from various industries.  Radianse remains focused on being committed to innovative research and development.  Radianse is applying its leadership and extensive networking knowledge along with inventive technology designs to launch new and advanced applications.  They are committed to innovation and delivering intelligent solutions for any industry.

Mass General Brigham is an integrated academic health care system that connects a full continuum of care across various medical facilities and services. The organization focuses on patient care, research, and education while advancing innovative solutions in medicine. It also serves as a principal teaching affiliate of Harvard Medical School, contributing significantly to biomedical research.

<div> Mass General Brigham, formerly known as Partners healthcare, is a non-profit, integrated healthcare system based in Boston, Massachusetts. Founded in 1994 by Brigham and Women's Hospital and Massachusetts General Hospital, Mass General Brigham is one of the largest health systems in the state, employing approximately 82,000 people and serving about 2.6 million patients. Mass General Brigham operates a network of hospitals, physician groups, community health centers, home care services, and other facilities. Its key member institutions include: <ul> <li> Massachusetts General Hospital </li> <li> Brigham and Women's Hospital </li> <li> Mass Eye and Ear </li> <li> McLean Hospital </li> <li> Cooley Dickinson Hospital </li> <li> Nantucket Cottage Hospital </li> <li> Mass General Brigham Community Physicians </li> <li> Mass General Brigham Health Plan </li> <li> Mass General Brigham Home Care </li> </ul> The system offers a wide range of medical services across its facilities, including primary care, specialty care, hospital care, and community-based programs. Mass General Brigham is also heavily involved in medical research, with an annual research budget of nearly USD 2 billion as of March 2024. Additionally, the system serves as a major teaching affiliate of Harvard Medical School. In recent years, Mass General Brigham has undertaken several strategic initiatives. In January 2023, the organization rebranded its health insurance arm from AllWays Health Partners to Mass General Brigham Health Plan. The system has also been working to more closely integrate its founding hospitals, announcing plans in March 2024 to merge clinical departments across Massachusetts General Hospital and Brigham and Women's Hospital. Mass General Brigham continues to focus on expanding its services and reach, aiming to leverage its combined strengths to enhance patient care and medical innovation. </div>

10 Mass General Brigham physicians to exit, join Beth Israel Lahey Health

Automation and robotics are finally creating solutions for the complexities of doorstep deliveries.

Last-mile Delivery Automation

ANALYST_QUICK_TAKE

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 Canadian drone solutions provider, Draganfly, partners with Mass General Brigham to use drones for delivering critical supplies to Home Hospital patients in Boston, Massachusetts. They will develop and map delivery routes to support patients and staff. The drones will carry critical medications, technical equipment, and laboratory work.
</div> Analyst QuickTake: Draganfly’s drones are mainly pitched toward other drone-based services for agriculture, military and government, and public safety industries. Draganfly previously partnered with Coldchain Technology Services for drone-based deliveries in the US, including <a href="https://finance.yahoo.com/news/draganfly-selected-immediately-develop-vaccine-141500387.html"> Covid-19 vaccine </a> deliveries and other <a href="https://www.geospatialworld.net/news/coldchain-delivery-systems-finalizes-750000-definitive-agreement-with-draganfly/"> medical supplies </a> deliveries.

Mass General Brigham

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless